Encyclopedia / Animal Pharmaceuticals / Auxiliaries and Other Medicinal Chemical... / Pharmaceutical Intermediates

Vorinostat

CAS：149647-78-9
MW:264.3202
MF：C14H20N2O3

A potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Induces differentiation in uman breast cancer cells. View more+

Email Tweet Share

Names and ldentifier
Properties
Use and Manufacturing
Msds
Other Information
Computational chemical data
Related Questions
Realated Product Infomation

1. Names and Identifiers

1.1 Name: Vorinostat

1.2 Synonyms: CS-1949; M344; N-Hydroxy-N'-phenyloctanediamide; Octanediamide, N1-hydroxy-N8-phenyl-; Octanediamide, N-hydroxy-N-phenyl-; SAHA; SAHA cpd; SAHA, N-Hydroxy-Nphenyloctanediamide, Zolinza; SAHA=N-Hydroxy-N'-phenyloctanediamide; suberanilohydroxamic acid; suberoylanilide hydroxamic acid; Suberoylanilidehydroxamic Acid; UNII-58IFB293JI; Vorinostat/SAHA; Vornostat; Zolinza; Zolinza (See Suberoylanilide Hydroxamic Acid);

View all

1.3 CAS No.: 149647-78-9

1.4 CID: 5311

1.5 EINECS: 1308068-626-2

1.6 Molecular Formula: C14H20N2O3

1.7 Inchi: InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)

1.8 InChkey: WAEXFXRVDQXREF-UHFFFAOYSA-N

1.9 Canonical Smiles: C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO

1.10 Isomers Smiles: C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO

2. Properties

2.1 Solubility: DMSO: ≥15mg/mL

2.2 Appearance: White Crystalline Solid

2.3 Storage: -20°C Freezer

2.4 Chemical Properties: White Crystalline Solid

2.5 Color/Form: white to tan

2.6 PH: pH = 6.6 (saturated water solution)

2.7 pKa: 9.48±0.20(Predicted)

2.8 Water Solubility: Soluble in ethanol (0.25 mg/ml), DMSO & DMF (20 mg/ml)

2.9 StorageTemp: -20°C

3. Use and Manufacturing

3.1 Definition: ChEBI: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

3.2 Description: It is the first HDAC inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) with significant skin involvement that is still progressing, resistant or relapsing after two systemic regimens. On October 6, 2006, the US Food and Drug Administration (FDA) have approved vorinostat capsules (vorinostat) for the treatment of skin cancer drugs. The drug is the first novel type of anti-cancer drugs of histone deacetylase inhibitor devel.

View all

3.3 Usage: A potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Induces differentiation in uman breast cancer cells.

4. MSDS

2.Hazard identification

2.1 Classification of the substance or mixture

Acute toxicity - Oral, Category 4

Germ cell mutagenicity, Category 2

Reproductive toxicity, Category 1B

Specific target organ toxicity \u2013 repeated exposure, Category 1

Hazardous to the aquatic environment, short-term (Acute) - Category Acute 1

Hazardous to the aquatic environment, long-term (Chronic) - Category Chronic 1

2.2 GHS label elements, including precautionary statements

Pictogram(s)
Signal word	Danger
Hazard statement(s)	H302 Harmful if swallowed H341 Suspected of causing genetic defects H360 May damage fertility or the unborn child H372 Causes damage to organs through prolonged or repeated exposure H400 Very toxic to aquatic life H410 Very toxic to aquatic life with long lasting effects
Precautionary statement(s)
Prevention	P264 Wash ... thoroughly after handling. P270 Do not eat, drink or smoke when using this product. P201 Obtain special instructions before use. P202 Do not handle until all safety precautions have been read and understood. P280 Wear protective gloves/protective clothing/eye protection/face protection. P260 Do not breathe dust/fume/gas/mist/vapours/spray. P273 Avoid release to the environment.
Response	P301+P312 IF SWALLOWED: Call a POISON CENTER/doctor/\u2026if you feel unwell. P330 Rinse mouth. P308+P313 IF exposed or concerned: Get medical advice/ attention. P314 Get medical advice/attention if you feel unwell. P391 Collect spillage.
Storage	P405 Store locked up.
Disposal	P501 Dispose of contents/container to ...

2.3 Other hazards which do not result in classification

none

View all

5. Synthesis Route

149647-78-9Total: 10 Synthesis Route

505-48-6 150 Suppliers

149647-78-9 183 Suppliers

3946-32-5 55 Suppliers

149647-78-9 183 Suppliers

View all

6. Precursor and Product

precursor:

162853-41-0

149647-86-9

74497-02-2

149648-52-2

3946-32-5

505-48-6

10521-06-9

7. Computed Properties

Molecular Weight：264.3202g/mol
Molecular Formula：C₁₄H₂₀N₂O₃
Compound Is Canonicalized：True
XLogP3-AA：264.14739250
Monoisotopic Mass：264.14739250
Complexity：276
Rotatable Bond Count：8
Hydrogen Bond Donor Count：3
Hydrogen Bond Acceptor Count：3
Topological Polar Surface Area：78.4
Heavy Atom Count：：19
Defined Atom Stereocenter Count：0
Undefined Atom Stereocenter Count：0
Defined Bond Stereocenter Count：0
Undefined Bond Stereocenter Count：0
Isotope Atom Count：0
Covalently-Bonded Unit Count：1
CACTVS Substructure Key Fingerprint：AAADceBzMAAAAAAAAAAAAAAAAAAAAAAAAAAwAAAAAAAAAAABAAAAHgAUCAAACAiBkAAwwILQAACIACVSUACCAAAhAgAoiAEAZIgIIDLAkZGEIAhglADIyAcYiICAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAA==

8.Other Information

Merck: 14,10034

Antitumor drugs: Vorinostat is a novel, molecularly targeted antineoplastic agent that causes cell cycle arrest and/or apoptosis by inhibiting histone deacetylase (HDAC). It is the first HDAC inhibitor approved by the US Food and Drug Administration (FDA) for the treatment of cutaneous T-cell lymphoma (CTCL) with significant skin involvement that is still progressing, resistant or relapsing after two systemic regimens.
On October 6, 2006, the US Food and Drug Administration (FDA) have approved vorinostat capsules (vorinostat) for the treatment of skin cancer drugs. The drug is the first novel type of anti-cancer drugs of histone deacetylase inhibitor developed by the United States Merck for the treatment of skin T cell lymphoma (CTCL). FDA has approved it for the treatment of metastatic skin T-cell lymphoma which is unable to be cured or even worsened or gets recurrent cases. A large number of experimental studies and clinical results have shown that vorinostat has a excellent efficacy on a variety of tumors and have significant synergies when combined with other oncology drugs. The current treatment of other tumors is still undergoing in-depth study; these results show that vorinostat has a broad market prospects.
Vorinostat has low toxicity with the evidence of its safety and efficacy being supported by two clinical trials, including 107 patients with CTCL who had gotten relapsed after receiving other drugs. According to the standard analysis of improvement in the grade of skin lesion, 30% of patients treated with Zolinza get symptoms improved, with the average efficacy duration of 168 days. The most common serious adverse events were pulmonary embolism, dehydration, deep venous thrombosis and anemia. Common adverse reactions are gastrointestinal symptoms (including diarrhea, nausea and loss of appetite, vomiting and constipation); fatigue, chills and taste disorders. Animal experiments showed that pregnant women should be banned of using the drug.

View all

Preparation: Suberic acid can undergo the intramolecular dehydration into suberic anhydride under the action of the acetic anhydride. The suberic anhydride, together with aniline can have ring-opening amidation in ethyl acetate at 0 °C to generate suberic acid monoanilide, followed by methanol esterification and hydroxylamine amine aminolysis to obtain the anti-tumor drug in vorinostat with the total yield of about 65%.
"Chinese Journal of Pharmaceutical Industry" 2009, Volume 40, No. 7, pages 481-483

View all

Anti-cancer drug Vorinostat was able to clear latent HIV virus: Researchers from the University of North Carolina at Chapel Hill have published a groundbreaking research paper in the July 25, 2012 issue of Nature to confirm that a deacetylase inhibitor drug – vorinostat that can be used to treat certain types of lymphoma-being capable of clearing out the patient's latent HIV virus in vivo.
The researchers have conducted a series of experiments to evaluate the potential of this drug to activate and destroy latent HIV viruses. Initially, laboratory experiments for measuring the level of active HIV in CD4 + T cells showed that vorinostat can take off the camouflage of latent HIV viruses in these cells. Then, eight male patients who still kept medically stable HIV infection after antiretroviral therapy, took vorinostat, and then were tested their active HIV levels in the body and compared it to the levels they had before taking the drug.
The researchers found that HIV-RNA levels in CD4 + T cells increased by an average of 4.5-fold in those patients who receiving vorinostat, confirming that the HIV virus was disguised. This is the first published study confirming that deacetylase inhibitors have the potential to break down latency in latent virus libraries. The study provides convincing evidence that a new strategy may be used to directly attack and eradicate latent HIV infection. However, getting rid of the latent nature of HIV is only the first step in curing HIV infection.

View all

Chemical Properties: White Crystalline Solid

Uses: A potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Induces differentiation in uman breast cancer cells.

Uses: antineoplastic, histone deacetylase inhibitor

Uses: Suberoylanilide Hydroxamic Acid is a potent, selective, cell permeable histone deacetylase inhibitor (HDAC). Suberoylanilide Hydroxamic Acid displays anti-angiogenic activity by interfering with VEGF signaling in human umbilical vein endothelial cells (HUVECs). Suberoylanilide Hydroxamic Acid induces differentiation in uman breast cancer cells.

View all

Uses: A potent HDAC inhibitor; also causes cell cycle arrest at G1

Definition: ChEBI: A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).

Target: Value

HDAC (Cell-free assay): ~10 nM

Preparation: Suberic acid can undergo the intramolecular dehydration into suberic anhydride under the action of the acetic anhydride. The suberic anhydride, together with aniline can have ring-opening amidation in ethyl acetate at 0 °C to generate suberic acid monoanilide, followed by methanol esterification and hydroxylamine amine aminolysis to obtain the anti-tumor drug in vorinostat with the total yield of about 65%.
"Chinese Journal of Pharmaceutical Industry" 2009, Volume 40, No. 7, pages 481-483

View all

Description: Vorinostat is the first drug in a new class of anti-cancer agents that inhibit histone deacetylases (HDAC). It was launched as an oral treatment for cutaneous manifestations in patients with cutaneous T-cell lymphoma (CTCL) who have progressive, persistent, or recurrent disease on or following two systemic therapies. HDACs are enzymes that catalyze the removal of the acetyl modification on lysine residues of proteins, including the core nucleosomal histones. Together with their counterpart histone acetyltransferases (HATs), HDACs regulate the acetylation level of the histones, which plays an important role in the regulation of chromatin plasticity and gene transcription. Hypoacetylation of histones is associated with a condensed chromatin structure resulting in the repression of gene transcription, whereas acetylated histones are associated with a more open chromatin structure and activation of transcription. In some cancer cells, there is an overexpression of HDACs, resulting in hypoacetylation of histones. Inhibitors of HDAC are thought to transcriptionally reactivate dormant tumor-suppressor genes by allowing for the accumulation of acetyl groups on histones and an open chromatin structure. Vorinostat inhibits the enzymatic activity of HDAC1, HDAC2, HDAC3, and HDAC6 at nanomolar concentrations (IC50 ＜86 nM). In vitro, it induces growth arrest, differentiation or apoptosis in a variety of tumor cells. In addition, vorinostat inhibits tumor growth in animal models bearing solid tumors, including breast, prostate, lung and gastric cancers, as well as hematologic malignancies such as multiple myeloma and leukemias.

View all

Originator: Columbia University (US)

Uses: Vorinostat, a histone deacetylase (HDAC) inhibitor from Merck, was approved for the treatment of cutaneous T-cell lymphoma (CTCL), a type of non-Hodgkin’s lymphoma. Vorinostat was shown to inhibit HDAC1, HDAC2, HDAC3 and HDAC6 at nanomolar concentrations. HDAC inhibitors are potent differentiating agents toward a variety of neoplasms, including leukemia and breast and prostate cancers.

View all

General Description: Histones are proteins around which DNA is wound in the process of packing DNA into the nucleus. They also havea role in regulating the transcription of genes, and this iscontrolled by the covalent modifications acetylation, phosphorylation,and methylation to which they are subject.
Vorinostat fits the basic pharmacophore for the HDACis, which consists of a hydrophobic cap regionconnected to a zinc coordinating functionality by a hydrophobiclinker.The hydroxamic acid functionality iscapable of bidendate binding to zinc present in the enzymeand is a major factor in the overall binding of the compound.The compound inhibits HDAC1, 2, 3, and 6 classes of thisenzyme with nanomolar (＜86 nM) IC50 values.
The agent is given orally and is available in 100-mg capsulesfor the treatment of cutaneous T-cell lymphoma. Thebioavailability is 43%, and the agent is 71% bound toplasma proteins. Extensive metabolism of the agent occursto give the O-glucuronide of the hydroxamic acid functionand 4-anilino-4-oxobutanoic acid with minimal involvementof isozymes of CYP. The metabolites, both of whichare inactive, are eliminated in the urine and the drug has aterminal elimination half-life of 2 hours. The most commonlyreported adverse effects are fatigue, diarrhea, andnausea.

View all

Biochem/physiol Actions: SAHA or Vorinostat facilitates the transcription of genes that result in apoptosis, differentiation and growth arrest. It has been observed to give beneficial results in lymphoma but not in solid tumors.

Chemical Synthesis: Commercially available monomethyl ester 125 was reacted with aniline in the presence of DCC and HOBt in DMF to give amide 127 in 89% yield.
Methyl ester amide 127 was then reacted with hydroxylamine HCl salt and potassium hydroxide in methanol to give vorinostat (XVI) in 90% yield.

View all

9. Toltal 168 Suppliers View more

High quality Vorinostat CAS 149647-78-9 supplied by Manufacturer

Tianjin Furun Tongda International Trade Co., LTD

^1YR

Tel: Update Time:2024/11/15

inquire

Wuhan Circle Star Chem-medical Technology Co.,Ltd

^1YR

Tel: Update Time:2024/11/15

inquire

Hebei Mojin Biotechnology Co.,Ltd

^1YR

Tel: Update Time:2024/11/15

inquire

chemical raw materials Vorinostat CAS:149647-78-9 with Optimal price

Hebei Crovell Biotech Co. Ltd

^1YR

Tel: Update Time:2024/11/15

inquire

Wuhan Fortuna Chemical Co., Ltd.

^1YR

Tel: Update Time:2024/08/08

inquire

10. Related Questions

: Can the anti-cancer drug Vorinostat really treat HPV infection?When asked about this type of question, friends who are not very familiar with this drug often cannot give a corresponding answer. Of course, to answer this question well, it is necessary to have a ce..; What is the efficacy of Vorinostat and its potential applications?Vorinostat is a group of histone deacetylase (HDAC) inhibitors that work by inducing cell differentiation, blocking the cell cycle, and inducing cell regulation. It is used to treat cutaneous T-cell l..; What are the instructions for Vorinostat?Background and overview[1][2] Vorinostat (vorinostat) is a deacetylase inhibitor (histone deacetylase inhibitor, HDACI). It can upregulate tumor suppressor genes by interfering with the activity of de..

11. Realated Product Infomation

Vorinostat impuritycas:866824-87-5